Press release - 02/03/2011 immatics appoints Dr. Harald Stock to its Board immatics biotechnologies GmbH, a late-stage biopharmaceutical company developing therapeutic vaccines that are active against cancer, today announced the appointment of Dr. Harald F. Stock to the board of directors, effective February 2011.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-dr-harald-stock-to-its-board
Press release - 24/11/2009 New impulses for the prevention of cancer Professor Cornelia Ulrich has been director of the Preventive Oncology Division in the National Centre for Tumour Diseases (NCT) in Heidelberg since mid-September 2009. She also holds a professorship in the Department of Preventive Oncology at the German Cancer Research Centre in Heidelberg.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-impulses-for-the-prevention-of-cancer
Press release - 19/11/2009 New scientific spokesperson of the German Society for Regenerative Medicine At this year’s general meeting of the German Society for Regenerative Medicine (GRM), Prof. Dr. Guido Nikkhah, Medical Director of the Department of Stereotactic Neurosurgery at the Neurocentre of the Freiburg University Medical Centre, was unanimously elected new scientific spokesperson of the GRM.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-scientific-spokesperson-of-the-german-society-for-regenerative-medicine
Big Data - 14/12/2017 Looking at the whole genome raises new questions Research laboratories around the world have long focused on studying the whole human genome. It is hoped that knowing the whole human genome will improve diagnostics and enable more specific therapies. Although genome analysis has not yet reached routine clinical application, whole genome sequencing has already raised many ethical and legal issues - for researchers, physicians and patients.https:////www.gesundheitsindustrie-bw.de/en/article/news/looking-at-the-whole-genome-raises-new-questions
Article - 30/06/2014 The German National Cohort: collecting data for a healthier future A large-scale long-term cohort study will be carried out to explain the causes of widespread diseases, in particular cancer, coronary heart disease, stroke and diabetes, and to identify the risk factors that lead to or favour the development of a certain disease. The principal objective of the German National Cohort (GNC) is to create the conditions that enable the development of new strategies for the prevention, risk assessment and early…https:////www.gesundheitsindustrie-bw.de/en/article/news/the-german-national-cohort-collecting-data-for-a-healthier-future
Researcher profile - 09/11/2015 Michael Boutros – from the study of social gene networks to the management of the DKFZ Deregulation of cell signalling pathways is a major driver of cancer. Prof. Dr. Michael Boutros has pioneered the development of new methods for the analysis of genetic interactions in such complex networks. He has been acting Chairman and Scientific Member of the Management Board of the German Cancer Research Center (DKFZ) since September 1st 2015. https:////www.gesundheitsindustrie-bw.de/en/article/news/michael-boutros-from-the-study-of-social-gene-networks-to-the-management-of-the-dkfz
Article - 20/04/2017 Health app to be integrated into clinical trials Questionnaires are a thing of the past, now it is becoming increasingly likely that information for clinical trials will be collected via apps in the future. A new research platform has been developed to prepare patient data transmitted via smartphone applications. Doctors who are carrying out research will thus have access to more accurate results that will also ultimately benefit patients. https:////www.gesundheitsindustrie-bw.de/en/article/news/health-app-to-be-integrated-into-clinical-trials
Article - 21/02/2019 Using neuromedical artificial intelligence responsibly Brain-computer interfaces are the latest developments in the neurotechnology field. They are used to record brain activity, which is then decoded with artificial intelligence techniques and converted into control signals for robots or computers. While this brings hope to severely paralysed people, it also implies risks due to the interest of companies like Google and Facebook in this type of data.https:////www.gesundheitsindustrie-bw.de/en/article/news/using-neuromedical-artificial-intelligence-responsibly
Article - 18/06/2012 Medical ethicists: biobanks need harmonization rather than new laws There are statutory European provisions on biobanks that regulate biobank research in Europe to a certain extent. Christian Lenk, managing director of the Ethics Commission at Ulm University, calls for the harmonization of existing European regulations rather than the creation of new laws. https:////www.gesundheitsindustrie-bw.de/en/article/news/medical-ethicists-biobanks-need-harmonization-rather-than-new-laws
Dossier - 18/06/2012 Biobanks – treasure chests for biomedical research Biobanking is still a very specialist subject. The Research Committee at the German Bundestag, the Office of Technology Assessment at the German Bundestag and the German Ethics Council are all interested in this biomedical research tool, which is both necessary and meaningful. However, opinions with regard to the ethical, legal and technical approach to biobanks differ. Since March 2012 it has become absolutely clear that Germany will not pass a…https:////www.gesundheitsindustrie-bw.de/en/article/dossier/biobanks-treasure-chests-for-biomedical-research